BNP PARIBAS FINANCIAL MARKETS - ACELRX PHARMACEUTICALS INC ownership

ACELRX PHARMACEUTICALS INC's ticker is ACRX and the CUSIP is 00444T100. A total of 78 filers reported holding ACELRX PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.18 and the average weighting 0.0%.

Quarter-by-quarter ownership
BNP PARIBAS FINANCIAL MARKETS ownership history of ACELRX PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2022$580,000
-14.5%
2,7740.0%0.00%
Q2 2022$678,000
-14.4%
2,7740.0%0.00%
Q1 2022$792,000
-52.9%
2,774
-7.6%
0.00%
Q4 2021$1,681,000
-73.7%
3,001
-52.1%
0.00%
Q3 2021$6,390,000
+46.9%
6,265
+98.8%
0.00%
Q2 2021$4,350,000
-92.3%
3,152
-90.5%
0.00%
Q1 2021$56,250,000
+167.4%
33,088
+95.0%
0.00%
Q4 2020$21,038,000
-22.9%
16,966
-11.7%
0.00%
Q3 2020$27,285,000
+428.5%
19,215
+350.3%
0.00%
Q2 2020$5,163,000
-81.9%
4,267
-82.3%
0.00%
Q1 2020$28,510,000
-16.2%
24,161
+49.8%
0.00%
Q4 2019$34,026,000
+55.3%
16,126
+61.9%
0.00%
Q3 2019$21,910,000
+70577.4%
9,959
+124387.5%
0.00%
Q3 2018$31,000
+14.8%
80.0%0.00%
Q2 2018$27,000
+58.8%
80.0%0.00%
Q1 2018$17,000
+6.2%
80.0%0.00%
Q4 2017$16,000
-56.8%
80.0%0.00%
Q3 2017$37,000
+117.6%
80.0%0.00%
Q2 2017$17,000
-90.7%
8
-86.2%
0.00%
Q1 2017$183,000
-89.3%
58
-91.2%
0.00%
Q4 2016$1,708,000
-81.8%
657
-72.7%
0.00%
Q3 2016$9,359,000
+148.5%
2,406
+71.9%
0.00%
Q2 2016$3,766,000
+67.6%
1,400
+140.5%
0.00%
Q1 2015$2,247,000
-73.0%
582
-61.6%
0.00%
Q3 2014$8,328,000
+143.8%
1,517
+402.3%
0.00%
Q4 2013$3,416,0003020.00%
Other shareholders
ACELRX PHARMACEUTICALS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Perceptive Advisors 6,574,060$27,874,0001.68%
SENZAR ASSET MANAGEMENT, LLC 798,381$3,385,0000.58%
Cormorant Asset Management, LP 850,000$3,604,0000.48%
Palo Alto Investors LP 2,135,739$9,056,0000.40%
Opus Point Partners Management, LLC 99,959$424,0000.34%
Granahan Investment Management 1,582,237$6,709,0000.19%
Joel Isaacson & Co., LLC 70,660$300,0000.08%
MARINER INVESTMENT GROUP LLC 59,700$253,0000.06%
MYCIO WEALTH PARTNERS, LLC 75,000$318,0000.06%
Cornerstone Capital, Inc. 59,200$251,0000.06%
View complete list of ACELRX PHARMACEUTICALS INC shareholders